36. 表皮水疱症 Epidermolysis bullosa Clinical trials / Disease details

臨床試験数 : 160 /  薬物数 : 195 - (DrugBank : 47) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 124

  
3 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04227106
(ClinicalTrials.gov)		January 10, 202010/1/2020Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)VIITAL: A Phase 3 Study of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)Epidermolysis Bullosa;Recessive Dystrophic Epidermolysis BullosaBiological: EB-101Abeona Therapeutics, IncNULLRecruiting6 YearsN/AAll15Phase 3United States
2NCT03632265
(ClinicalTrials.gov)		October 1, 201817/7/2018Study of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis BullosaVITAL: A Pivotal Phase 3 Study of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) (GENE TRANSFER)Recessive Dystrophic Epidermolysis BullosaBiological: EB-101Jean Yuh TangAbeona Therapeutics, IncNot yet recruiting6 YearsN/AAll15Phase 3NULL
3NCT03183934
(ClinicalTrials.gov)		July 20178/6/2017A Follow-up Study to Evaluate the Efficacy and Safety of ALLO-ASC-DFU in ALLO-ASC-EB-101 Clinical TrialA Follow-up Study to Evaluate the Efficacy and Safety for the Patients With ALLO-ASC-DFU Treatment in Phase 1/2 Clinical Trial of ALLO-ASC-EB-101Dystrophic Epidermolysis BullosaBiological: ALLO-ASC-DFUAnterogen Co., Ltd.NULLNot yet recruiting2 Years60 YearsAll5Phase 1/2Korea, Republic of